AirXpanders

AirXpanders, Inc. was a medical device company founded in 2005, dedicated to improving breast reconstruction outcomes. The company specialized in designing, manufacturing, and marketing innovative devices, with its flagship product being the AeroForm Tissue Expander System. This device was used in two-stage breast reconstruction following mastectomy and allowed patients to control tissue expansion at home using carbon dioxide gas, providing an alternative to traditional saline expanders. The AeroForm Tissue Expander received several regulatory approvals, including U.S. FDA de novo marketing authorization in 2016 and market clearance in 2017, as well as CE marking in Europe in 2012. The product was also licensed for sale in Australia. AirXpanders primarily generated revenue from U.S. customers, with a smaller portion from Australia. The company was publicly traded on the Australian Securities Exchange under the symbol "AXP."

• Employees 1
• Founded 2005
• Annual Revenue $7800000
• Total Funding $73886635